Manuel Ascano

Dr. Manuel Ascano

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2019 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
DSDaniel Shae
Daniel Shae
KBKyle W. Becker
Kyle W. Becker
PCPlamen Christov
Plamen Christov
DYDong Soo Yun
Dong Soo Yun
ALAbigail K. R. Lytton-Jean
Abigail K. R. Lytton-Jean
JWJohn T. Wilson
John T. Wilson

29 September 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
JVJessica Vincent
Jessica Vincent
CACarolina Adura
Carolina Adura
PGPu Gao
Pu Gao
ALAntonio Luz
Antonio Luz
LLLodoe Lama
Lodoe Lama
MAManuel Ascano
Manuel Ascano
Cyclic GMP-AMP synthase is essential for innate immunity against infection and cellular damage, serving as a sensor of DNA from pathogens or mislocalized self-DNA. Upon binding double-stranded DNA, cyclic GMP-AMP synthase synthesizes a cyclic dinucleotide that initiates an inflammatory cellular response. Mouse studies that recapitulate causative mutations in the autoimmune disease Aicardi-Goutières syndrome demonstrate that ablating the cyclic GMP-AMP synthase gene abolishes the deleterious phenotype. Here, we report the discovery of a class of cyclic GMP-AMP synthase inhibitors identified by a high-throughput screen. These compounds possess defined structure-activity relationships and we present crystal structures of cyclic GMP-AMP synthase, double-stranded DNA, and inhibitors within the enzymatic active site. We find that a chemically improved member, RU.521, is active and selective in cellular assays of cyclic GMP-AMP synthase-mediated signaling and reduces constitutive expression of interferon in macrophages from a mouse model of Aicardi-Goutières syndrome. RU.521 will be useful toward understanding the biological roles of cyclic GMP-AMP synthase and can serve as a molecular scaffold for development of future autoimmune therapies.

6 May 2020 in Molecular Cell
Verified
Journal Article
Closed access
BKByungil Kim
Byungil Kim
SASarah Arcos
Sarah Arcos
KRKatherine Rothamel
Katherine Rothamel
JJJeffrey Jian
Jeffrey Jian
KRKristie L. Rose
Kristie L. Rose
MAManuel Ascano
Manuel Ascano

1 May 2021 in Cell Reports
Verified
Journal Article
Open access
KRKatherine Rothamel
Katherine Rothamel
SASarah Arcos
Sarah Arcos
BKByungil Kim
Byungil Kim
CRClara Reasoner
Clara Reasoner
SLSamantha Lisy
Samantha Lisy
MAManuel Ascano
Manuel Ascano
Upon pathogen detection, the innate immune system triggers signaling events leading to upregulation of pro-inflammatory and anti-microbial mRNA transcripts. RNA-binding proteins (RBPs) interact with these critical mRNAs and regulate their fates at the post-transcriptional level. One such RBP is ELAVL1. Although significant progress has been made in understanding how embryonic lethal vision-like protein 1 (ELAVL1) regulates mRNAs, its target repertoire and binding distribution within an immunological context remain poorly understood. We overlap four high-throughput approaches to define its context-dependent targets and determine its regulatory impact during immune activation. ELAVL1 transitions from binding overwhelmingly intronic sites to 3' UTR sites upon immune stimulation of cells, binding previously and newly expressed mRNAs. We find that ELAVL1 mediates the RNA stability of genes that regulate pathways essential to pathogen sensing and cytokine production. Our findings reveal the importance of examining RBP regulatory impact under dynamic transcriptomic events to understand their post-transcriptional regulatory roles within specific biological circuitries.

4 July 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NBNicholas J. Barrows
Nicholas J. Barrows
YAYesseinia Anglero-Rodriguez
Yesseinia Anglero-Rodriguez
BKByungil Kim
Byungil Kim
SJSharon F. Jamison
Sharon F. Jamison
CSCaroline Le Sommer
Caroline Le Sommer
MGMariano Garcia-Blanco
Mariano Garcia-Blanco
Hundreds of cellular host factors are required to support dengue virus infection, but their identity and roles are incompletely characterized. Here, we identify human host dependency factors required for efficient dengue virus-2 (DENV2) infection of human cells. We focused on two, TTC35 and TMEM111, which we previously demonstrated to be required for yellow fever virus (YFV) infection and others subsequently showed were also required by other flaviviruses. These proteins are components of the human endoplasmic reticulum membrane protein complex (EMC), which has roles in ER-associated protein biogenesis and lipid metabolism. We report that DENV, YFV and Zika virus (ZIKV) infections were strikingly inhibited, while West Nile virus infection was unchanged, in cells that lack EMC subunit 4. Furthermore, targeted depletion of EMC subunits in live mosquitoes significantly reduced DENV2 propagation in vivo. Using a novel uncoating assay, which measures interactions between host RNA-binding proteins and incoming viral RNA, we show that EMC is required at or prior to virus uncoating. Importantly, we uncovered a second and important role for the EMC. The complex is required for viral protein accumulation in a cell line harboring a ZIKV replicon, indicating that EMC participates in the complex process of viral protein biogenesis.

5 May 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CWCaroline Wiser
Caroline Wiser
BKByungil Kim
Byungil Kim
JVJessica Vincent
Jessica Vincent
MAManuel Ascano
Manuel Ascano
The cGAS-STING pathway is a major mechanism that mammalian cells utilize to detect cytoplasmic dsDNA from incoming viruses, bacteria, or self. CYCLIC GMP-AMP SYNTHASE (cGAS) is the sensor protein that directly binds dsDNAs. cGAS synthesizes cyclic GMP-AMP (cGAMP), which binds to the adaptor STIMULATOR OF INTERFERON GENES (STING), activating an INTERFERON REGULATORY FACTOR 3 (IRF3)-mediated immune response. Constitutive activation can result in interferonopathies such as Aicardi-Goutieres Syndrome (AGS) or other lupus-like autoimmune disorders. While inhibitors targeting mouse or human cGAS have been reported, the identification of a small molecule that targets both homologs of cGAS has been challenging. Here, we show that RU.521 is capable of potently and selectively inhibiting mouse and human cGAS in cell lines and human primary cells. This inhibitory activity requires the presence of cGAS, but it cannot suppress an immune response in cells activated by RNA, Toll-like receptor ligands, cGAMP, or recombinant interferon. Importantly, when RU.521 is applied to cells, the production of dsDNA-induced intracellular cGAMP is suppressed in a dose-dependent manner. Our work validates the use of RU.521 for probing DNA-induced innate immune responses and underscores its potential as an ideal scaffold towards pre-clinical development, given its potency against human and mouse cGAS.